Literature DB >> 22994586

Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.

M Fabbiani1, N Ciccarelli, M Tana, S Farina, E Baldonero, V Di Cristo, M Colafigli, E Tamburrini, R Cauda, M C Silveri, P Grima, S Di Giambenedetto.   

Abstract

OBJECTIVES: The aim of the study was to investigate the relationship between metabolic comorbidities, cardiovascular risk factors or common carotid intima-media thickness (cIMT) and cognitive performance in HIV-infected patients.
METHODS: Asymptomatic HIV-infected subjects were consecutively enrolled during routine out-patient visits at two clinical centres. All patients underwent an extensive neuropsychological battery and assessment of metabolic comorbidities and cardiovascular risk factors. Moreover, cIMT was assessed by ultrasonography. Cognitive performance was evaluated by calculating a global cognitive impairment (GCI) score obtained by summing scores assigned to each test (0 if normal and 1 if pathological).
RESULTS: A total of 245 patients (median age 46 years; 84.1% with HIV RNA < 50 copies/mL; median CD4 count 527 cells/μL) were enrolled in the study. Cardiovascular risk factors were highly prevalent in our population: the most frequent were dyslipidaemia (61.2%), cigarette smoking (54.3%) and hypertension (15.1%). cIMT was abnormal (≥ 0.9mm) in 31.8% of patients. Overall, the median GCI score was 2 [interquartile range (IQR) 1-4]; it was higher in patients with diabetes (P = 0.004), hypertension (P = 0.030) or cIMT ≥ 0.9 mm (P < 0.001). In multivariate analysis, it was confirmed that diabetes (P = 0.007) and cIMT ≥ 0.9 mm (P = 0.044) had an independent association with lower cognitive performance. In an analysis of patients on combination antiretroviral therapy (cART), abacavir use was independently associated with a better cognitive performance (P = 0.011), while no association was observed for other drugs or neuroeffectiveness score.
CONCLUSIONS: Diabetes, cardiovascular risk factors and cIMT showed a strong association with lower cognitive performance, suggesting that metabolic comorbidities could play a relevant role in the pathogenesis of HIV-associated neurocognitive disorders in the recent cART era.
© 2012 British HIV Association.

Entities:  

Mesh:

Year:  2012        PMID: 22994586     DOI: 10.1111/j.1468-1293.2012.01044.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  32 in total

1.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

2.  Impact of aging on neurocognitive performance in previously antiretroviral-naive HIV-infected individuals on their first suppressive regimen.

Authors:  Hamza Coban; Kevin Robertson; Marlene Smurzynski; Supriya Krishnan; Kunling Wu; Ronald J Bosch; Ann C Collier; Ronald J Ellis
Journal:  AIDS       Date:  2017-07-17       Impact factor: 4.177

3.  The current understanding of overlap between characteristics of HIV-associated neurocognitive disorders and Alzheimer's disease.

Authors:  Leah H Rubin; Erin E Sundermann; David J Moore
Journal:  J Neurovirol       Date:  2019-01-22       Impact factor: 2.643

Review 4.  Successful cognitive aging and health-related quality of life in younger and older adults infected with HIV.

Authors:  Raeanne C Moore; Pariya L Fazeli; Dilip V Jeste; David J Moore; Igor Grant; Steven Paul Woods
Journal:  AIDS Behav       Date:  2014-06

5.  Identifying risk factors for HIV-associated neurocognitive disorders using the international HIV dementia scale.

Authors:  Sara Cross; Nur Önen; Amber Gase; Edgar Turner Overton; Beau M Ances
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-10       Impact factor: 4.147

6.  Hepatitis C virus-related factors associated WITH cognitive performance in HIV-HCV-coinfected patients.

Authors:  Massimiliano Fabbiani; Nicoletta Ciccarelli; Valeria Castelli; Alessandro Soria; Alberto Borghetti; Elisa Colella; Davide Moschese; Manuela Valsecchi; Arianna Emiliozzi; Andrea Gori; Andrea De Luca; Alessandra Bandera; Simona Di Giambenedetto
Journal:  J Neurovirol       Date:  2019-07-07       Impact factor: 2.643

7.  Differences in Neurocognitive Impairment Among HIV-Infected Latinos in the United States.

Authors:  María J Marquine; Anne Heaton; Neco Johnson; Monica Rivera-Mindt; Mariana Cherner; Cinnamon Bloss; Todd Hulgan; Anya Umlauf; David J Moore; Pariya Fazeli; Susan Morgello; Donald Franklin; Scott Letendre; Ron Ellis; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Ned Sacktor; David Simpson; J Allen McCutchan; Igor Grant; Robert K Heaton
Journal:  J Int Neuropsychol Soc       Date:  2017-09-06       Impact factor: 2.892

8.  Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients.

Authors:  N Ciccarelli; M Fabbiani; P Grima; K Falasca; M Tana; E Baldonero; M Colafigli; M C Silveri; J Vecchiet; R Cauda; S Di Giambenedetto
Journal:  Infection       Date:  2013-07-10       Impact factor: 3.553

Review 9.  HIV and aging: effects on the central nervous system.

Authors:  Silvia Cañizares; Mariana Cherner; Ronald J Ellis
Journal:  Semin Neurol       Date:  2014-04-08       Impact factor: 3.420

Review 10.  Neurologic Complications of Human Immunodeficiency Virus Infection.

Authors:  Deanna Saylor
Journal:  Continuum (Minneap Minn)       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.